Insiders Have Traded Agios Pharmaceuticals Inc. (AGIO) Stock In What Way?

The stock of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) increased by $0.55 on Wednesday to $18.64, up 3.01 percent. The last five days have seen an average of 1,164,651 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$14.35. The average number of shares traded over the last 20 days was 732,488, while the average volume over the last 50 days totaled 701,885.

AGIO stock dropped -12.23% since last month. On 06/16/22, the company’s shares reached a one-month low of $16.75. The stock touched a high of $61.28 on 01/05/22, after rallying from a low of $16.75 in 52 weeks. The price of AGIO stock has declined by -44.97% or -$14.35 this year, reaching a new high 3 times. Still, the stock price is down -69.59% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Insider Transactions

There have been 117 days since Agios Pharmaceuticals Inc. (AGIO) last reported insider trading activity on Feb 25. On Feb 25, Principal Accounting Officer Washburn Theodore James Jr. sold 108 shares at $30.00 each. This transaction resulted in the insider making $3,240. On Feb 16, Washburn Theodore James Jr. sold 233 shares at a price of US$30.81. After the transaction, the insider now owns 2,549 shares. Principal Accounting Officer Washburn Theodore James Jr. had earlier sold 504 shares on Feb 14 for $31.25 a share. The transaction was completed for $15,750.

Valuation Metrics

Beta for the stock is 1.51. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1181.73, the price-to-book (PB) ratio of 0.82.

Financial Health

For the three months ended March 30, Agios Pharmaceuticals Inc.’s quick ratio was 21.20, while its current ratio was 21.30, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 59.30% percent.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. AGIO’s return on assets (ROA) during the last 12 months has been -23.50%. In the meantime, the return on equity (ROE) for the last 12 months was -26.00%.

Earnings Surprise

According to Agios Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended March 30, it had $843.5 million in cash and short-term investments. Net income for the quarter came in at $0.83 million, while revenues rose by 100.0% to $0.0. It was predicted that Agios Pharmaceuticals Inc.’s quarterly earnings would be -$1.74, but it ended up being -$1.81, beating the consensus by 3.90%. EBITDA was -$97.52 million for the quarter. At the end of Agios Pharmaceuticals Inc.’s most recent quarter ended March 30, its liabilities totaled 128.41 million, while its total debt was $97.09 million. Equity owned by shareholders amounts to $54.79 million.

Technical Picture

Here’s a quick look at Agios Pharmaceuticals Inc.’s (AGIO) price momentum from a technical perspective. As of 21 June, the RSI 9-day stood at 47.64%, suggesting the stock is Neutral, with a 74.28% historical volatility rate.

The stochastic %K and %D were 37.54% and 31.64% respectively, while the average true range (ATR) was 1.25. Based on the 14-day stochastic reading of 45.96%, the RSI (14) reading is 44.10%. On the 9-day MACD Oscillator, the stock is at 0.13, and the 14-day reading is at -0.35.

Analyst Ratings

In its analyst report released on December 03, 2021, BofA Securities began covering Agios Pharmaceuticals Inc. (NASDAQ: AGIO). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Agios Pharmaceuticals Inc. (AGIO) an Overweight rating. AGIO is a stock that is recommended for selling by 1 brokerage firm, while 4 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.

What is AGIO’s price target for the next 12 months?

The current consensus forecast for the stock is between $16.00 and $48.00, with a median target price of $41.50. In analyzing these forecasts, the average price target given by analysts for Agios Pharmaceuticals Inc. (AGIO) is $37.83.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam